Fig. 3 | Modern Pathology

Fig. 3

From: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies

Fig. 3

Effect of PD-L1 mutations on the binding of PD-L1 antibodies. Expi293F cells were transfected with a WT PD-L1, WT PD-L2, or PD-L1 constructs with mutations in the cytoplasmic domain of PD-L1 and b mutations in the extracellular domain of PD-L1. PD-L1 binding was detected by western blotting using SP263, SP142, E1L3N, 28-8, and 22C3 antibodies. GAPDH Glyceraldehyde 3-phosphate dehydrogenase, PD-L1 programmed cell death ligand-1, PD-L2 programmed cell death ligand-2, P2-P1, construct containing the extracellular domain of PD-L2 fused to the last 27 residues of the PD-L1 cytoplasmic domain, WT wild-type

Back to article page